NASDAQ:LNTH - Lantheus Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.44 +0.17 (+1.28 %) (As of 10/15/2018 04:00 PM ET)Previous Close$13.27Today's Range$13.14 - $13.6552-Week Range$12.80 - $24.45Volume263,500 shsAverage Volume363,490 shsMarket Capitalization$572.58 millionP/E Ratio13.46Dividend YieldN/ABeta1.33 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts. Receive LNTH News and Ratings via Email Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical SymbolNASDAQ:LNTH CUSIPN/A Webwww.lantheus.com Phone978-671-8001 Debt Debt-to-Equity Ratio5.94 Current Ratio3.86 Quick Ratio3.14 Price-To-Earnings Trailing P/E Ratio13.46 Forward P/E Ratio15.45 P/E Growth3.44 Sales & Book Value Annual Sales$331.38 million Price / Sales1.55 Cash Flow$1.4237 per share Price / Cash9.44 Book Value$0.62 per share Price / Book21.68 Profitability EPS (Most Recent Fiscal Year)$1.00 Net Income$123.38 million Net Margins37.53% Return on Equity560.19% Return on Assets9.05% Miscellaneous Employees483 Outstanding Shares38,300,000Market Cap$572.58 million Lantheus (NASDAQ:LNTH) Frequently Asked Questions What is Lantheus' stock symbol? Lantheus trades on the NASDAQ under the ticker symbol "LNTH." How were Lantheus' earnings last quarter? Lantheus Holdings Inc (NASDAQ:LNTH) released its earnings results on Wednesday, August, 1st. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of $0.22 by $0.04. The medical equipment provider had revenue of $85.60 million for the quarter, compared to analyst estimates of $87.90 million. Lantheus had a net margin of 37.53% and a return on equity of 560.19%. The business's quarterly revenue was down 3.6% compared to the same quarter last year. During the same period last year, the firm earned $0.35 EPS. View Lantheus' Earnings History. When is Lantheus' next earnings date? Lantheus is scheduled to release their next quarterly earnings announcement on Thursday, November 1st 2018. View Earnings Estimates for Lantheus. What price target have analysts set for LNTH? 3 Wall Street analysts have issued 12-month price targets for Lantheus' stock. Their predictions range from $20.00 to $27.00. On average, they expect Lantheus' share price to reach $22.6667 in the next twelve months. This suggests a possible upside of 68.7% from the stock's current price. View Analyst Price Targets for Lantheus. What is the consensus analysts' recommendation for Lantheus? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus. Who are some of Lantheus' key competitors? Some companies that are related to Lantheus include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Riot Blockchain (RIOT), ImmuCell (ICCC), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF) and Fluoropharma Medical (FPMI). Who are Lantheus' key executives? Lantheus' management team includes the folowing people: Ms. Mary Anne Heino, CEO, Pres & Director (Age 58)Mr. John W. Crowley, CFO & Treasurer (Age 54)Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 57)Mr. John J. Bolla, Sr. VP of Technical Operations & DirectorMs. Meara Murphy, Director of Investor Relations & Corp. Communications When did Lantheus IPO? (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.56%). Company insiders that own Lantheus stock include Avista Capital Partners Gp, Ll, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Timothy G Healey. View Institutional Ownership Trends for Lantheus. Which major investors are buying Lantheus stock? LNTH stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Lantheus. How do I buy shares of Lantheus? Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Lantheus' stock price today? One share of LNTH stock can currently be purchased for approximately $13.44. How big of a company is Lantheus? Lantheus has a market capitalization of $572.58 million and generates $331.38 million in revenue each year. The medical equipment provider earns $123.38 million in net income (profit) each year or $1.00 on an earnings per share basis. Lantheus employs 483 workers across the globe. What is Lantheus' official website? The official website for Lantheus is http://www.lantheus.com. How can I contact Lantheus? Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected] MarketBeat Community Rating for Lantheus (NASDAQ LNTH)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 199 (Vote Outperform)Underperform Votes: 174 (Vote Underperform)Total Votes: 373MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/15/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?